+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175793
  • Report
  • August 2020
  • Region: North America
  • 80 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc
  • Bayer AG
  • Cerulean Pharma Inc
  • Eisai co Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
The North America Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period. The major factors driving the growth of the market in the North America region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

According to GLOBOCAN 2018, in 2018, there were about 60,336 new kidney cancer cases and the mortality was approximately 15,333 cases in the United States.

Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the North America kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.

Key Market Trends

Clear cell RCC Segment is Expected to Hold Major Market Share in the North America Kidney Cancer Therapeutics & Diagnostics Market

Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.

As per the National Cancer Institute of the United States, in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.

For people without symptoms, these tumors can be discovered if the person has an imaging test as well. Another method to detect ccRCC is biopsy. To check if the tumor is ccRCC, the physician performs a biopsy, taking a small sample from the tumor with a needle. The sample is studied under the microscope to see what kind of tumor it is.

Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib. Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.

Competitive Landscape

The North America Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Abbott Laboratories, Amgen Inc, and Seattle Genetics.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc
  • Bayer AG
  • Cerulean Pharma Inc
  • Eisai co Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.3.2 Preference for Generic Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Clear cell RCC
5.1.2 Papillary RCC
5.1.3 Chromophobe RCC
5.1.4 Urothelial carcinoma/Transitional cell carcinoma
5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
5.2 By Component
5.2.1 Drugs
5.2.1.1 Therapeutic Class
5.2.1.1.1 Targeted Therapy
5.2.1.1.2 Immunotherapy
5.2.1.1.3 Other Therapeutic Class
5.2.1.2 Pharmacologic Class
5.2.1.2.1 Angiogenesis Inhibitors
5.2.1.2.2 Monoclonal Antibodies
5.2.1.2.3 mTOR Inhibitors
5.2.1.2.4 Cytokine Immunotherapy (IL-2)
5.2.2 Diagnostics
5.2.2.1 Biopsy
5.2.2.2 Imaging Tests
5.2.2.3 Blood Tests
5.2.2.4 Other Diagnostics
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Bayer AG
6.1.4 Novartis AG
6.1.5 Amgen Inc
6.1.6 Abbott Laboratories
6.1.7 Cerulean Pharma Inc
6.1.8 Eisai co Ltd
6.1.9 Seattle Genetic
6.1.10 GlaxoSmithKline PL

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Novartis AG
  • Amgen Inc
  • Abbott Laboratories
  • Cerulean Pharma Inc
  • Eisai co Ltd
  • Seattle Genetic
  • GlaxoSmithKline PL
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll